Biotech recent Insider Buying: Inovio Pharmaceuticals (NYSEMKT:INO), Agios Pharmaceuticals (NASDAQ:AGIO), Synta Pharmaceuticals (NASDAQ:SNTA), OHR Pharmaceutical (NASDAQ:OHRP)

Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $2.63 moved to $2.66 on last trade day and at the end of the day closed at $2.60. Company price to sales ratio in past twelve months was calculated as 46.25 and price to cash ratio as 11.87. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -7.14%.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares fell -8.88% in last trading session and ended the day on $40.00. Agios Pharmaceuticals Inc (NASDAQ:AGIO) return on equity ratio is recorded as -193.90% and its return on assets is -31.90%.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of Synta Pharmaceuticals Corp. stock on the open market in a transaction dated Friday, April 11th.  Synta Pharmaceuticals Corp. (NASDAQ:SNTA) closed at $4.09 while trading in range of $3.93 – $4.24 – Synta Pharmaceuticals Corp. (NASDAQ:SNTA) year to date (YTD) performance is -21.95%.

OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff acquired 5,500 shares of OHR Pharmaceutical stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average cost of $10.25 per share, for a total transaction of $56,375.00.  OHR Pharmaceutical Inc (NASDAQ:OHRP) weekly performance is -2.54%. On last trading day company shares ended up $9.59.  OHR Pharmaceutical Inc (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is -34.92%. Analysts mean target price for the company is $21.00.